CURX
Curanex Pharmaceuticals Inc0.4059
-0.0170-4.02%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
11.50MP/E (TTM)
-Basic EPS (TTM)
-0.02Dividend Yield
0%Recent Filings
8-K
Execs sign paid deals
Curanex locked in CEO Jun Liu and COO Dr. Liqin Xie with new employment agreements effective March 1, 2026—$393,600 base for Liu, $180,000 for Xie—after years of unpaid service. Both pacts enforce strict 18-month non-competes guarding botanical IP, plus 3-month severance on no-cause exits. Leadership secured.
8-K
CFO resigns; Zhang appointed
Curanex Pharmaceuticals' CFO Haiyan Yang resigned effective December 31, 2025, with no disagreements cited. Wanjun Zhang, with 20+ years in finance including Nasdaq reporting stints, steps in as CFO via consulting agreement starting January 1, 2026, at $20,000 yearly for two years. Zhang handles SEC filings remotely as independent contractor. Smooth transition bolsters compliance.
10-Q
Q3 FY2025 results
Curanex posted a Q3 net loss of $954K, up from $91K last year, driven by $677K in new R&D for FDA-mandated IND studies in ulcerative colitis and other inflammatory diseases, while G&A rose to $274K on IPO costs. Operating loss hit $951K versus $93K prior year; net loss widened slightly due to $4K interest on repaid shareholder loans. Cash swelled to $5.8M post-$15.3M IPO proceeds in August-September 2025, funding $8.5M prepaid R&D. No revenue yet. Nasdaq bid price below $1.00 flags delisting risk.
8-K
Nasdaq bid price deficiency notice
Curanex Pharmaceuticals received a Nasdaq notice on November 5, 2025, for its common stock's closing bid price staying below $1.00 over 30 consecutive business days, violating Listing Rule 5550(a)(2). Nasdaq granted a 180-day compliance period until May 4, 2026, to hit $1.00 for 10 straight business days. Stock trades uninterrupted as CURX. Delisting looms without fix.
8-K
Debt repaid, shares issued
Curanex Pharmaceuticals issued 28,312 shares of common stock to investor Xiaohong Song on September 25, 2025, fulfilling a $200,000 subscription from November 2024 post-IPO, representing 0.1% of outstanding shares under a Section 4(a)(2) exemption. The company prepaid $408,537.32 to settle two $200,000 promissory notes from CEO's wife Dian Ying Jing, wiping out all outstanding debt and avoiding $26,182.68 in future interest. Debt cleared. This bolsters the balance sheet after the August IPO.
ACXP
Acurx Pharmaceuticals, Inc.
3.59-0.10
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
CNTB
Connect Biopharma Holdings Limi
2.36+0.06
CPMD
Cannapharmarx Inc.
0.00-0.00
CUBT
CURATIVE BIOTECHNOLOGY INC.
0.01+0.00
IMA
ImageneBio, Inc.
6.25+0.08
NXEN
Nexien BioPharma, Inc.
0.00+0.00
TRML
Tourmaline Bio, Inc.
47.98+47.98
TTNP
Titan Pharmaceuticals, Inc.
4.61-0.18
XCUR
Exicure, Inc.
6.06+0.33